ALNY241220C220000
- 33.20
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Alnylam Downgraded at Wolfe on Doubts Over Amvuttra Growth
Alnylam Pharmaceuticals Analyst Ratings
Wolfe Research Downgrades Alnylam Pharmaceuticals(ALNY.US) to Sell Rating, Announces Target Price $205
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Alnylam Pharma's Promising Pipeline and Strong Financials Justify Buy Rating and $400 Target
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $371
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $300 to $384
Alnylam Pharmaceuticals Is Maintained at Buy by Chardan Capital
Alnylam Pharmaceuticals Analyst Ratings
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $366
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $371
TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Alnylam Pharmaceuticals Analyst Ratings